Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3465657 | 1.00 | SPHK1 (0.44) | SPHK1BRD4HSD11B2GLAHCRTR2 | |
| SCHEMBL3467057 | 0.85 | SPHK1 (0.45) | SPHK1BRD4HSD11B2HCRTR2 | |
| SCHEMBL3467056 | 0.85 | SPHK1 (0.45) | SPHK1BRD4HSD11B2HCRTR2 | |
| SCHEMBL14357932 | 0.83 | SPHK1 (0.46) | SPHK1BRD4HSD11B2GLAHCRTR2 | |
| SCHEMBL8445237 | 0.83 | SPHK1 (0.46) | SPHK1BRD4HSD11B2GLAHCRTR2 | |
| SCHEMBL3466633 | 0.83 | SPHK1 (0.46) | SPHK1BRD4HSD11B2HCRTR2 | |
| SCHEMBL3466629 | 0.83 | SPHK1 (0.46) | SPHK1BRD4HSD11B2HCRTR2 | |
| SCHEMBL31362264 | 0.81 | SPHK1 (0.47) | SPHK1BRD4HSD11B2GLAHCRTR2 | |
| SCHEMBL3614792 | 0.81 | SPHK1 (0.45) | SPHK1BRD4HSD11B2HCRTR2 | |
| SCHEMBL3614794 | 0.81 | SPHK1 (0.45) | SPHK1BRD4HSD11B2HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767690-B2 | Amino alcohol derivatives and their use as renin inhibitor | NOVARTIS AG (CH) | 2010-08-03 | — | — | US | disclosed |
| US-20090118281-A1 | Amino Alcohol Derivatives And Their Use As Renin Inhibitor | NOVARTIS AG (CH) | 2009-05-07 | — | — | US | disclosed |
| EP-1711456-A2 | AMINO ALCOHOL DERIVATIVES AND THEIR USE AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005070870-A2 | AMINO ALCOHOL DERIVATIVES AND THEIR USE AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118281-A1 | Amino Alcohol Derivatives And Their Use As Renin Inhibitor | REN, AGTR1, ADH1A | SPHK1 3516/4885BRD4 956/4885HSD11B2 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.